Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
PDF) Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
SJIA Clinical Trial Safety Profile Side Effects | ACTEMRA® (tocilizumab)
COVID-19 Clinical Trials Safety Side Effects | ACTEMRA® (tocilizumab)
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial - The Lancet Rheumatology
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Subcutaneous Injections for RA | ACTEMRA® (tocilizumab)
JCM | Free Full-Text | Treatment of Giant Cell Arteritis (GCA)
PDF) Long-term treatment with tocilizumab in giant cell arteritis: Efficacy and safety in a monocentric cohort of patients
About ACTEMRA® (tocilizumab) Treatment Info for Healthcare Professionals
TOCILIZUMAB
Actemra Side Effects: Common, Severe, Long Term - Drugs.com
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
How is Actemra® (tocilizumab) for GCA believed to work?
Tocilizumab for relapsing and remitting giant cell arteritis: a case series | Journal of Medical Case Reports | Full Text
JCM | Free Full-Text | Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study
Single Technology Appraisal Tocilizumab for treating giant cell arteritis Committee Papers
Frontiers | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
PDF) Long-term effects of tocilizumab therapy for uveitic macular edema
PJIA Safety Profile Side Effects | ACTEMRA® (tocilizumab)
Pharmaceutics | Free Full-Text | Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
Actemra (Tocilizumab) Shortage Is Still Affecting Rheumatology Patients
Arthritis drug that helps Covid ICU patients has wider benefits, trial finds | Coronavirus | The Guardian
Cutaneous Adverse Effects of Surface-Targeted Monoclonal Antibodies – Consult QD
Side effects with Tocilizumab and suggested management. | Download Table
Hundreds died while taking an arthritis drug, but nobody alerted patients
Frontiers | Tocilizumab and COVID-19: Timing of Administration and Efficacy
Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis
